Translational Immunology

The aim of this conference is to bridge the translational gap in immunopathology, bringing together clinicians, research scientists and industry partners to discuss prominent advances from the bench to the clinic. The different sessions will have a particular focus on precision medicine in general, starting from disease-oriented cases and lessons learned. Innovative and alternative therapeutic strategies in immune-mediated disorders will be presented, besides the regulatory challenges that companies and researchers are dealing with.

Travel Grants

We offer 5 travel grants to international attendees, which will reimburse travel costs up to 400 Euros. Are you interested in attending TransImmu20 and want to have a chance on a travel grant? Submit your motivation below by clicking on the 'Apply for a grant' button before 7 January 2020. The organizing committee will notify you of your travel grant acceptance on 14 January 2020. No registration is needed before submitting a travel grant proposal. When you’re awarded with a travel grant you will receive a practical email containing the next steps. Note that being awarded a travel grant does not mean being registered for the conference. Scroll down to apply for your grant.

Information for poster submissions

The format for your poster should be: A0 (841 x 1189 mm / 33.1 x 46.8 in), portrait orientation. The deadline for the abstracts is 27 January 2020. The best four abstracts were given a short talk slot in the plenary program.

Deadlines:

  • Travel Grant deadline: 7 January 2020
  • Abstract submission: 27 January 2020
  • Early Bird deadline: 13 February 2020
  • Late Registration deadline: 13 March 2020

Speakers:

  • Richards S. Blumberg, Harvard Medical School, US
  • Anthony Coyle, CEO, Pandion Therapeutics, US
  • Dirk Elewaut, VIB-UGent Center for Inflammation Research, BE
  • Alain Fischer, Assistance publique – Hôpitaux de Paris, FR
  • Martin Guilliams, VIB-UGent Center for Inflammation Research, BE
  • Bengt Hoepken, Clinical Program Director, UCB Pharma, DE
  • Isabelle Huys, KU Leuven, BE
  • Christophe Lahorte, National Innovation Office & Scientific-Technical Advice Unit - Federal Agency For Medicines And Healthcare Products (Famhp)
  • Bart Lambrecht, VIB-UGent Center for Inflammation Research, BE
  • Antonio Lanzavecchia, Institute for Research in Biomedicine, CH
  • Melanie Matheu, CEO, Founder at Prellis Biologics, Inc., US
  • Kathy McCoy, University of Calgary, CA
  • Eoin McKinney, University of Cambridge, UK
  • Fiona Powrie, Kennedy Institute of Rheumatology, University of Oxford, UK
  • Maria Grazia Roncarlo, Stanford, US
  • Federica Sallusto, Institute for Research in Biomedicine, CH
  • Georg Schett, Friedrich-Alexander University Erlangen-Nürnberg, DE
  • René van Lier, Sanquin, NL
  • Séverine Vermeire, Translational Research in GastroIntestinal Disorders, KU Leuven, BE
  • Sally Ward, University Of Southampton, UK
  • Laurance Zitvogel, Gustave Roussy, INSERM, University Paris Saclay, FR
TransImmu20

Date:

Location:

Onderbergen 1
9000 Ghent, Belgium
View on Google maps

Organized by:

Other Events